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Purpose: To examine if sonic hedgehog (Shh) is involved in tissue neovascularization by using cell culture and an animal
cornea.
Methods: The effects of exogenous Shh (5.0 nM), vascular endothelial growth factor (VEGF), and/or a Shh signal inhibitor
(2.5 or 10.0 μM cyclopamine) on vessel-like tube formation of vascular endothelial cells were examined in vitro. The
effects of Shh on the expression of angiogenic cytokines in cultured cell types were examined in cultured cells. The
expression of Shh and its receptor, Patched 1 (Ptc), was examined in a vascularized mouse cornea during post-alkali burn
healing. The effect of exogenous Shh on corneal neovascularization in vivo was assayed using a rat cornea system. The
effect of a topical injection of cyclopamine on cauterization-induced corneal neovascularization was then studied.
Results: Adding Shh promoted vessel-like tube formation of vascular endothelial cells. This effect was counteracted by
addition of cyclopamine. Cyclopamine did not affect VEGF-enhanced tube formation. Shh did not affect the expression
levels of angiogenic cytokines in cultured cell types. mRNA and protein expression levels of Shh and Ptc were under the
detection limit in an uninjured cornea, but Shh but not Ptc was upregulated in a healing, alkali-burned, vascularized cornea.
Exogenous Shh promoted neovascularization (NV) formation in vivo in a rat cornea. Topical cyclopmine blocked Gli
signaling (blocked translocation of Gli3) and the length of neovascularization in the peripheral cornea post-cauterization
as compared with the control vehicle-treated cornea.
Conclusions: Shh enhances endothelial tube formation independently through VEGF signaling in vitro. Shh signaling is
involved in the development of unfavorable corneal neovascularization in animal corneas.
Vascular  growth  (neovascularization,  NV)  might  be
beneficial to tissue repair in an injured tissue. For example,
vessel growth is essential in a survival skin graft [1]. However,
the cornea is an avascular tissue of the eye and must remain
transparent to refract light properly. Therefore, injury-induced
NV is one of the unfavorable factors that potentially impairs
patients’  vision.  Cytokines/growth  factors  are  believed  to
orchestrate cell behavior during the development of NV in a
healing cornea. Although transforming growth factor (TGF)
β, vascular endothelial cell growth factor (VEGF), and tumor
necrosis factor (TNF) α are believed to have central roles in
corneal NV development, other factors must be involved [2,
3]. Sonic hedgehog (Shh) is a morphogen and is a secretory
protein of molecular weight 20 kDa. Shh is known to be
involved not only in embryonic organogenesis but also in
development  of  malignant  neoplasms  such  as  basal  cell
carcinoma or other cancers [4-12]. Upon Shh binding to the
receptor composed of patched 1 (Ptc) and Smoothend (Smo),
the Shh signal transmitter, Gli members, are activated and
translocated to the cell nuclei for gene expression regulation.
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For example, Shh signaling upregulates cyclin D1, leading to
cell proliferation promotion [13].
As for eye tissues, the pathobiology of Shh signaling is
to be investigated. We previously reported that Shh but not
the Ptc Shh receptor is upregulated in the healing rat corneal
epithelium  post-debridement  and  that  Shh  promotes  cell
proliferation in the healing epithelium of a mouse cornea
[14]. It has also been reported that Shh signaling is beneficial
in wound healing in the skin and heart, but the effects might
depend  on  the  induction  of  neovascularization,  which  is
critical in the repair process in such tissues [15,16]. Moreover,
Shh  is  reportedly  involved  in  not  only  cell  proliferation
regulation but also NV development during the progression
of malignant tumors [17,18].
However, the role of Shh in a complicated corneal healing
process such as that seen in a cornea burned with alkali has
not been investigated. In such, cornea NV could be one of the
key factors that influences unfavorable stromal opacification
in a healing cornea, such as the generation of myofibroblasts.
In the present study, we first investigated the role of Shh
signaling in NV formation by using a co-culture system of
vein endothelial cells and fibroblasts. We then examined if
Shh is expressed in a post-alkali burned, neovascularized,
healing corneal stroma and if exogenous Shh promotes NV
formation in a rat cornea. We finally examined if blocking Shh
signaling suppresses NV in a cornea by using cyclopamine.
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1036This  compound  binds  Ptc  and  Smo  in  the  Shh  receptor
complex and inhibits Shh signaling [14,19].
METHODS
Experiments were approved by the Animal Care and Use
Committee of Wakayama Medical University (Wakayama,
Japan) and conducted in accordance with the Association for
Research in Vision and Ophthalmology Statement for the Use
of Animals in Ophthalmic and Vision Research.
Assay  for  vessel-like  tube  formation  by  vascular
endothelial cells: A commercially available co-culture system
of human umbilical vein endothelial cells (HUVECs) and
human fibroblasts (NV kit; Kurabo, Tokyo, Japan) was used
according to the manufacturer’s protocol. In this kit, HUVECs
form vessel-like tube tissues that are labeled with anti-CD31
antibody on a fibroblast feeder layer. HUVECs were seeded
on a fibroblast feeder layer in the wells of two-well culture
plates.  Recombinant  Shh  (5.0  nM;  R&D  systems,
Minneapolis, MN) alone or Shh (5.0 nM) and cyclopamine
(2.5 or 10.0 μM; Toronto Research Chemicals, North York,
Ontario, Canada) was added to the culture medium at days 1,
2, 4, and 7 of culture. The control culture did not contain these
compounds. The cultures were fixed with 70% ethanol on day
11 of culture and processed for immunocytochemistry for
CD31.  The  antibody  complex  was  visualized  with
diaminobenzidine  as  previously  reported  [14].  Four  wells
were prepared for each culture condition. The total length and
the  number  of  branching  points  were  counted  in  five
independent points in each well.
To  examine  if  Shh  signaling  is  involved  in  VEGF-
dependent  vessel-like  tube  formation,  we  conducted  the
following  experiment.  The  culture  was  treated  with
recombinant VEGF (10.0 ng/ml) or VEGF plus cyclopamine
(2.5 or 10.0 μM) and assessment of tube formation was as
described  above.  Statistical  analysis  was  conducted  by
employing Turkey-Kramer’s test, and p<0.05 was taken as
statistically significant.
Alkali burn model in adult mice: An alkali burn was
produced with 3 ml of 1 N topical NaOH in the cornea of an
adult  C57BL/6  mouse  (n=42)  under  general  and  topical
anesthesia as previously reported [20,21] and allowed to heal
for up to 5, 10, or 20 days. Cryosections and paraffin sections
fixed  with  cold  acetone  were  processed  for
immunohistochemistry with goat anti-Shh antibody or anti-
Ptc antibody (20 μg/ml in phosphate-buffered saline [PBS];
R&D  systems).  Histology  was  examined  by  using
hematoxylin and eosin (HE) staining.
Real-time  reverse  transcription  polymerase  chain
reaction (RT–PCR) was also performed to detect mRNAs of
Shh and Ptc in a healing, alkali-burned cornea. The cornea of
a C57BL/6 mouse (n=29) was burned with 1 N NaOH as
described above. An uninjured cornea served as the control.
Two days later total RNA was extracted from the excised
cornea. The RNA sample was analyzed using TaqMan real-
time RT–PCR, (Applied Biosystems, Tokyo, Japan) a primer
set, and a TaqMan probe for Shh or Ptc (ABI Assay ID:
Mm00436527 or Mm00436031)
Effects of exogenous Shh on expression of angiogenic
cytokine expression in cultured cells: To examine if Shh is
capable of inducing angiogenic cytokines in epithelial and
mesenchymal cell types, we performed an in vitro experiment
and an enzyme-linked immunosorbent assay (ELISA). The
Araki-Sasaki  human  corneal  epithelial  cell  line  or  mouse
fibroblasts  were  cultured  until  confluency  in  either
Dulbecco’s  modified  Eagle’s  medium  (DMEM)
supplemented  with  5%  fetal  calf  serum  or  DMEM
supplemented with 15% fetal calf serum. Each cell type was
then incubated in serum-free DMEM for 24 h. The cells were
then cultured in the presence of recombinant Shh (2.5 nM, 5.0
nM, 10.0 nM; R&D systems). After an incubation for 24 h,
the culture medium was harvested and processed for ELISA
assay  (Quantikine;  R&D  Systems)  of  TGFβ1,  VEGF,  or
Monocyte Chemotactic Protein-1 (MCP-1). Cells were also
processed for total RNA extraction and real-time RT–PCR for
mRNAs of human or mouse TGFβ1, VEGF, and MCP-1 using
the TaqMan one step system with the primers and TaqMan
probes as previously reported [2,22,23].
Effect  of  cyclopamine  on  development  of  corneal
neovascularization  in  vivo:  Corneal  NV  from  the  limbal
vessels  was  induced  by  two  methods,  central  corneal
cauterization in one eye of individual mice using implantation
of  a  Shh-containing  polymer  pellet  to  the  stroma  or
cauterization  by  a  disposable  Optemp  tool  (Mod-Tronic
Instruments, Brampton, ON, Canada) as previously reported
[3].
We first examined the direct effect of exogenous Shh on
corneal NV formation using implantation of a Shh-containing
polymer pellet to the corneal stroma. Adult Wistar rats (n=20)
were used. The polymer pellets were prepared as follows.
Polyethylene-co-vinyl  acetate  (Sigma-Aldrich,  St.  Louis,
MO)  was  dissolved  in  1,1-dinitroethane  (30%  solution  in
ethylene chloride) in a water bath (37 °C) for 30 min at the
final concentration of 100 mg/ml. The polymer solution was
set in a glass dish and dissected to obtain small pieces of the
pellets (1 mm×1 mm×0.1 mm). Four treatment groups were
prepared: 1) control without exogenous agents; 2) a polymer
pellet containing recombinant Shh (50 μg/ml in phosphate-
buffered saline [PBS]; R&D systems); 3) a polymer pellet
with  cyclopamine  (2.5  mg/ml  in  PBS,  Toronto  Reserch
Chemicals); and 4) with recombinant Shh (50 μg/ml in PBS
+  cyclopamine  [2.5  mg/ml  in  PBS]).  Each  pellet  was
implanted into the peripheral corneal stroma as follows. A
pocket was produced with a surgical blade in the peripheral
cornea of a Wistar rat (n=20) that was generally anesthetized
with intra peritoneal (i.p.) entobarbital sodium. Each pellet
was inserted into the pocket of the stroma, and ofloxacin
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infection.  Ten  days  after,  We  evaluated  development  of
corneal NV. The length of the NV was statistically analyzed
by using the Turkey-Kramer method, and a p<0.05 was taken
as statistically significant.
Next,  to  know  the  role(s)  of  endogenous  Shh  on
cauterization-induced NV formation, cyclopamine (2.5 mg/
ml in PBS) or PBS alone was injected into retrobulbar tissue
using  a  hypodermic  needle  at  the  time  of  cauterization.
Experimental mice were sacrificed seven days after injury.
The eye was then enucleated and subjected to HE histology
and  cryosection  for  immunohistochemistry  of  CD31  and
nuclear translocation of Gli3, the signaling molecule of Shh.
The length of NV in the peripheral cornea was measured and
analyzed using the Wilcoxon signed ranks test. P values less
than 0.05 were taken as statistically significant.
RESULTS
Effects of exogenous Shh on expression of angiogenic cytokine
expression in cultured cells: In both cell types of Araki-Sasaki
corneal epithelial cells and mouse fibroblasts, exogenous Shh
did not affect the protein and mRNA expression level of
TGFβ1, VEGF, and MCP-1 until 24 h after Shh (2.5 μm, 5.0
μm, 10.0 μm) incubation (Figure 1).
Vessel-like  tube  tissue  formation  by  HUVECs:  When
evaluated by the measurement of the total length of vessel-
like  tubes  formed  by  HUVECs,  data  in  Shh  (5.0  nmol/l)
treated cultures and in Shh (5.0 nmol/l) plus cyclopamine (2.5
mmol/l) treated cultures were significantly higher than the
data in the control culture. Further addition of cyclopamine at
2.5 mM and 10.0 mM significantly suppressed Shh-induced
vessel-like tube formation as evaluated by its total length
(Figure 2). Similarly, adding Shh enhanced the total number
of branching points of the tube and such enhancement was
counteracted by the further addition of cyclopamine.
The effect of cyclopamine on VEGF-supported vessel-
like tube formation by HUVECs was also examined. The
addition of cyclopamine (2.5 mM and 10.0 mM) to VEGF
treated cultures did not significantly alter the total length and
the number of branching points in vessel-like tube structure
(Figure 3).
Histology of an alkali-burned cornea: At day 5 post-alkali
burn,  minor  NV  was  observed  in  the  peripheral  cornea
adjacent to the limbus. At day 20, marked NV was found to
grow from the limbus toward the central cornea (Figure 4).
Shh mRNA expression in an alkali-burned cornea: Real-time
RT–PCR was performed to detect Shh mRNA expression in
a healing, alkali-burned cornea. The expression level of Shh
mRNA was under the detection limit in the uninjured cornea
while  Shh  mRNA  expression  was  certainly  detected  at  a
markedly high level (approximately 227 fold compared with
control) in an alkali-burned cornea. On the other hand, Ptc
mRNA  expression  level  was  unchanged  during  wound
healing in an alkali-burned cornea (data not shown).
Immunohistochemistry:  To  define  which  cell  type(s)
express(es) Shh, we then performed immunohistochemistry.
As previously reported by us [14], Shh was not detected in the
corneal stroma of an uninjured cornea (data not shown) but
was upregulated in both the healing epithelium and stroma
(Figure 5A,C,E) until day 20. Corneal neovascularization as
labeled for CD31 was observed in the cornea from day 5 to
day 20 post-burn (Figure 5B,D,F). Shh expression was more
marked in the area of stroma with neovascularization.
Figure 1. Effects of exogenous Sonic
hedgehog  on  the  expression  of
angiogenic  cytokine  expression  in
cultures of mouse fibroblasts and Araki-
Sasaki corneal epithelial cells. In both
cell types, adding exogenous Shh does
not affect mRNA expression levels of
transforming growth factor β1 (TGFβ1;
A),  monocyte/macrophage-
chemoattractant protein-1 (MCP-1; B),
or  vascular  endothelial  growth  factor
(VEGF; C).
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1038Role of exogenous Shh and cyclopamine on development of
corneal  stromal  neovascularization  in  vivo:  We  first
examined a direct effect of exogenous Shh on corneal NV
formation. We employed implantation of a Shh-containing
polymer  pellet  to  the  corneal  stroma.  Implantation  of  a
polymer pellet containing recombinant Shh induced marked
NV in the stroma from the limbal vessels compared with
control  corneas,  indicating  that  Shh  has  a  NV-promoting
effect in vivo just as it does in vitro. A pellet containing
cyclopamine  reduced  NV  formation  compared  with  the
control, indicating that endogenous Shh also has a promoting
role in the development of corneal NV. Cyclopamine indeed
counteracted exogenous Shh-induced NV. (Figure 6)
Effect of cyclopamine on the development of cauterization-
induced  corneal  neovascularization  in  vivo:  We  then
examined the role(s) of endogenous Shh on injury-induced
corneal NV formation, although the experiment above by
using an implantation of a pellet to the cornea suggested both
exogenous  and  endogenous  Shh  is  involved  in  NV
development. Cauterization in the central cornea induced NV
Figure 2. Effects of exogenous Sonic
hedgehog  on  in  vitro  angiogenesis  in
HUVECs  on  fibroblast  feeder  layer.
Exogenenous  Sonic  hedgehog  (Shh)
enhances  CD31-labeled,  vessel-like
tube tissue formation when compared
with  the  control  co-culture.  Such
enhancement  of  tube  formation  by
exogenous Shh is suppressed by further
addition of cyclopamine (A-C). Bar, 50
mm. Adding recombinant Shh at 5.0 nM
promoted the formation of vessel-like
tube formation in HUVECs as evaluated
by the total length of the structure (D)
and the number of the branching points
(E).  Further  addition  of  cyclopamine
(2.5  or  10.0  μM)  suppressed  the
elongation  and  branching  of  the  tube
structure.
Figure 3. Effects of cyclopamine on in vitro angiogenesis in HUVECs on fibroblast feeder layer. Tube formation in the presence of vascular
endothelial growth factor (VEGF) was not affected by the addition of cyclopamine at the concentrations of 2.5 and 10.0 ng/ml as revealed by
the evaluation of the total length of CD31-positive tissue (A) and the numbers of its branching (B).
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1039in  the  peripheral  cornea  as  previously  reported  [20,21].
Topical  cyclopamine  decreased  the  length  of
neovascularization in the peripheral cornea post-cauterization
when compared with the control vehicle-treated cornea seven
days after injury (Figure 7A-C). In these specimens, we then
examined the expression of Shh and the nuclear translocation
of  Gli3.  Immunohistochemistry  showed  that  not  only  the
nuclear translocation but also further induction of Shh in tissue
were  suppressed  by  topical  treatment  with  cyclopamine
(Figure 7D-G).
DISCUSSION
In the present study, we first examined if exogenous Shh
promotes NV formation. We then conducted an in vitro co-
culture experiment by using fibroblast feeder and HUVECs.
This in vitro experiment showed that adding recombinant Shh
accelerated  vessel-like  tube  formation  by  HUVECs,
suggesting  a  promoting  role  of  Shh  in  NV  development.
Counteraction  of  cyclopamine  to  Shh-enhanced  tube
formation further suggested the role of Shh there. The total
length of tube-like tissue might depend on endogenous Shh
because  its  total  length  in  cyclopamine  culture  (data  not
shown)  or  Shh+cyclopamine  culture  (Figure  2B)  was
significantly  less  compared  with  that  seen  in  the  control
culture.  It  was  reported  that  Shh  upregulates  VEGF  in
endothelial progenitor cells isolated from human peripheral
blood but did not upregulate VEGF in HUVECs, primary
dermal microvascular endothelial cells, or fibroblasts [24,
25]. Cyclopamine did not affect the total length or the number
of branching points of the in vitro vessel-like structure in the
presence of exogenous VEGF, suggesting that Shh signaling
is independent of VEGF signaling. Exogenous Shh promoted
the development of corneal NV. We then tested whether this
phenomenon  is  observed  in  vivo  in  animal  corneas.  We
detected upregulation of Shh in a healing stroma of an alkali-
burned neovascularized mouse cornea, suggesting that Shh
might have a role in the development of NV in a healing
cornea. The expression level of Ptc, the Shh receptor, did not
change  during  healing  in  an  alkali-burned  cornea.  As
discussed later, blocking endogenous Shh by cyclopamine
attenuated NV formation in a mouse cornea. Shh reportedly
enhances NV-dependent tissue repair in skin and heart [15,
16]. However, NV is unfavorable to maintain/recover the
vision/transparency of a patient with a corneal injury and thus
should be suppressed.
As described above in the in vitro experiment, the VEGF-
promoted tube formation was not affected by further addition
of  cyclopamine,  suggesting  that  Shh  signaling  is  not  not
located downstream of VEGF signaling. It has been reported
that cyclopamine attenuates vasculogenesis in the developing
Figure 4. Histology of burned corneas stained with hematoxylin and eosin. On day 5 (A) and 10 (B), neovascularization is observed in the
limbal region of an alkali-burned cornea. Neovascularization is detected even in the central cornea at day 20 (C,D). Bar, 50 μm.
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1040mouse heart in association with suppressing VEGF expression
[26].  It  has  also  been  reported  that  Shh  upregulates  the
expressions of VEGF and angiopoietin-1,-2 in cultured human
lung fibroblasts [27]. On the other hand, exogenous Shh does
not affect the expression level of VEGF in mouse vascular
endothelial  cells  in  vitro  [28].  Explanations  for  this
discrepancy include the differences in condition, differences
in cell types, and in vivo versus in vitro. In vivo Shh signaling
might affect VEGF expression in the cells adjacent to the new
vessels, i.e., fibroblasts or bone marrow-derived pericytes
[29].  During  the  in  vitro  condition,  the  newly  developed
vessel-like structure is composed of vascular endothelial cells.
The in vivo condition behavior of such pericytes or other
vessel supporting mesenchymal cells might be modulated by
Shh signaling.
These results finally led us to hypothesize that blocking
Shh signaling might have a beneficial inhibitory effect on NV
development in the cornea. To explore this hypothesis we
conducted an in vivo experiment. Shh, but not the Ptc receptor,
was upregulated in a vascularized healing mouse cornea post-
alkali burn. The exact mechanism of upregulation of Shh
expression in a healing, injured cornea needs to be explored.
We  have  reported  that  the  healing  corneal  epithelium
following  debridement  express  Shh  [14],  suggesting  that
activation of cells upon injury might switch on its expression.
We therefore examined a direct effect of exogenous Shh on
corneal NV formation. We employed an implantation of a
Figure 5. Expression pattern of Sonic hedgehog and CD31 in alkali-burned corneas. On day 5 (A,B) and 20 (C,D), neovascularization in the
limbal region was stained for Sonic hedgehog (Shh; FITC). The healing epithelium as well as the stroma were labeled for Shh (C). On day
20, CD31-labeled (Rhodamin) neovascularization was observed in the area of the corneal stroma stained for Shh (E,F). Bar, 50 μm.
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1041Shh-containing  polymer  pellet  to  the  corneal  stroma.
Implantation of a polymer pellet containing recombinant Shh
induced marked NV in the stroma from limbal vessels when
compared with control corneas, indicating that Shh has a NV-
promoting  effect  in  vivo,  the  same  as  in  vitro.  A  pellet-
containing  cyclopamine  reduced  NV  formation  when
compared the with control, indicating that endogenous Shh
also has a promoting role in the development of corneal NV.
Cyclopamine  indeed  counteracted  exogenous  Shh-induced
NV. We then examined the roles of endogenous Shh on injury-
induced  corneal  NV  formation,  although  the  experiment
above suggested that both exogenous and endogenous Shh is
involved in NV development. Cauterization at the center of
the cornea induced NV development in the corneal periphery,
and  this  NV  formation  was  suppressed  by  topical
administration  (injection  into  retrobulbar  tissue)  of
cyclopamine, indicating that cyclopamine’s inhibitory effect
on NV formation was even observed in vivo. In the present
study, we used injections into the retrobulbar tissue instead of
systemic  administration.  Although  animal  species  are
different (a primate versus mouse), it was reported that the
concentration of an anti-cancer drug in the vitreous humor was
much  higher  when  topically  administered  to  the  orbit  as
compared with via systemic administration [30]. These results
indicate  that  endogenous  Shh/Gli  signaling  is  actually
involved in the development of corneal NV.
Shh signaling is also reportedly involved in NV formation
in experimental models of choroidal NV or retinal NV. This
report also shows that Shh activation is located upstream of
VEGF  in  experimental  retinal  neovascularization  under
retinal  hypoxic  conditions  because  inhibition  of  the  Shh
pathway results in the reduction of VEGF level along with that
of Patched-1 (Ptch1), a canonical Shh target. In the present
study  of  a  mouse  cornea,  blocking  Shh  signaling  might
directly  affect  the  cells  involved  in  NV  tissue  because
blocking Shh signaling by using cyclopamine does not affect
Figure 6. Effect of exogenous Sonic hedgehog on the development of corneal neovascularization in vivo. A-D: Implantation of a polymer
pellet-containing recombinant Shh induced marked NV in the stroma from limbal vessels (B) as compared with control corneas (A), indicating
that Shh has a NV-promoting effect in vivo like in vitro. Pellet containing cyclopamine reduced NV formation as compared with control (C,
D), indicating that endogenous Shh also has a promoting role in the development of corneal NV. Cyclopamine indeed counteracted exogenous
Shh-induced NV. B shows the length of the NV developed from limbus in each group of treatment (E).
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1042the expression level of VEGF in cultured corneal epithelial
cells and fibroblasts. The exact mechanism underlying this
discrepancy is has yet to be explored [31].
Our experiment suggests that Shh signaling is a potential
target to prevent and/or treat unfavorable NV formation in the
cornea.
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